Rhenman & Partners Asset Management AB
Latest statistics and disclosures from Rhenman & Partners Asset Management AB's latest quarterly 13F-HR filing:
- Top 5 stock holdings are LLY, BSX, BMRN, REGN, MCK, and represent 20.28% of Rhenman & Partners Asset Management AB's stock portfolio.
- Added to shares of these 10 stocks: LLY (+$10M), CRL (+$8.6M), PRCT (+$7.0M), ISRG (+$6.9M), MDT (+$6.5M), BSX (+$6.3M), SWAV, LNTH, HCA, VRTX.
- Started 4 new stock positions in DXCM, CRL, OSCR, CNC.
- Reduced shares in these 10 stocks: CI (-$10M), ZBH (-$8.8M), ELV (-$7.8M), UNH (-$7.1M), , HRMY, OM, TXG, VEEV, BIIB.
- Sold out of its positions in MOH, RIGL.
- Rhenman & Partners Asset Management AB was a net buyer of stock by $42M.
- Rhenman & Partners Asset Management AB has $928M in assets under management (AUM), dropping by -2.23%.
- Central Index Key (CIK): 0001599882
Tip: Access up to 7 years of quarterly data
Positions held by Rhenman & Partners Asset Management AB consolidated in one spreadsheet with up to 7 years of data
Download as csv Download as ExcelPortfolio Holdings for Rhenman & Partners Asset Management AB
Rhenman & Partners Asset Management AB holds 85 positions in its portfolio as reported in the September 2023 quarterly 13F filing
Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
---|---|---|---|---|---|---|
Eli Lilly & Co. (LLY) | 5.8 | $54M | +23% | 100k | 537.13 |
|
Boston Scientific Corporation (BSX) | 4.0 | $37M | +20% | 700k | 52.80 |
|
BioMarin Pharmaceutical (BMRN) | 3.6 | $34M | 380k | 88.48 |
|
|
Regeneron Pharmaceuticals (REGN) | 3.5 | $33M | +14% | 40k | 822.96 |
|
McKesson Corporation (MCK) | 3.3 | $31M | 71k | 434.85 |
|
|
Medtronic SHS (MDT) | 3.2 | $29M | +28% | 375k | 78.36 |
|
Vertex Pharmaceuticals Incorporated (VRTX) | 2.9 | $27M | +20% | 77k | 347.74 |
|
Abbott Laboratories (ABT) | 2.7 | $25M | +5% | 262k | 96.85 |
|
Becton, Dickinson and (BDX) | 2.6 | $25M | 95k | 258.53 |
|
|
Humana (HUM) | 2.6 | $24M | +6% | 49k | 486.52 |
|
UnitedHealth (UNH) | 2.5 | $23M | -23% | 46k | 504.19 |
|
Cigna Corp (CI) | 2.5 | $23M | -30% | 80k | 286.07 |
|
Abbvie (ABBV) | 2.4 | $22M | 150k | 149.06 |
|
|
Tenet Healthcare Corp Com New (THC) | 2.4 | $22M | +15% | 335k | 65.89 |
|
AmerisourceBergen (COR) | 2.3 | $21M | 119k | 179.97 |
|
|
CVS Caremark Corporation (CVS) | 2.3 | $21M | +20% | 300k | 69.82 |
|
Hca Holdings (HCA) | 2.2 | $20M | +28% | 83k | 245.98 |
|
Intuitive Surgical Com New (ISRG) | 2.1 | $20M | +53% | 68k | 292.29 |
|
Merck & Co (MRK) | 2.1 | $20M | 190k | 102.95 |
|
|
Cooper Cos Com New (COO) | 2.1 | $19M | +13% | 60k | 317.75 |
|
Jazz Pharmaceuticals Shs Usd (JAZZ) | 2.0 | $19M | 144k | 129.44 |
|
|
Gilead Sciences (GILD) | 1.9 | $18M | 234k | 74.94 |
|
|
Anthem (ELV) | 1.8 | $17M | -32% | 38k | 435.42 |
|
Procept Biorobotics Corp (PRCT) | 1.7 | $16M | +76% | 493k | 32.81 |
|
Shockwave Med (SWAV) | 1.7 | $16M | +44% | 81k | 199.10 |
|
Danaher Corporation (DHR) | 1.6 | $15M | 60k | 248.10 |
|
|
Biogen Idec (BIIB) | 1.6 | $15M | -12% | 57k | 257.01 |
|
Axonics Modulation Technolog (AXNX) | 1.4 | $13M | 230k | 56.12 |
|
|
Natera (NTRA) | 1.3 | $12M | +33% | 267k | 44.25 |
|
Lantheus Holdings Inc Common Stock Usd 0.01 (LNTH) | 1.3 | $12M | +68% | 168k | 69.48 |
|
ImmunoGen (IMGN) | 1.2 | $11M | -6% | 700k | 15.87 |
|
EXACT Sciences Corporation (EXAS) | 1.2 | $11M | -8% | 160k | 68.22 |
|
Privia Health Group (PRVA) | 1.1 | $11M | 460k | 23.00 |
|
|
Alkermes SHS (ALKS) | 1.1 | $10M | +5% | 370k | 28.01 |
|
Dynavax Technologies Corp Com New (DVAX) | 1.1 | $10M | 700k | 14.77 |
|
|
Iqvia Holdings (IQV) | 1.0 | $9.2M | 47k | 196.75 |
|
|
Charles River Laboratories (CRL) | 0.9 | $8.6M | NEW | 44k | 195.98 |
|
Alignment Healthcare (ALHC) | 0.9 | $8.3M | +20% | 1.2M | 6.94 |
|
Apellis Pharmaceuticals (APLS) | 0.9 | $8.2M | +13% | 215k | 38.04 |
|
Alnylam Pharmaceuticals (ALNY) | 0.9 | $8.0M | 45k | 177.10 |
|
|
Mirati Therapeutics (MRTX) | 0.8 | $7.6M | +25% | 175k | 43.56 |
|
Zimmer Holdings (ZBH) | 0.7 | $6.7M | -56% | 60k | 112.22 |
|
Immunovant (IMVT) | 0.7 | $6.4M | +66% | 166k | 38.39 |
|
Neurocrine Biosciences (NBIX) | 0.7 | $6.1M | +36% | 55k | 112.50 |
|
Karuna Therapeutics Ord (KRTX) | 0.6 | $5.9M | 35k | 169.09 |
|
|
Cytokinetics Com New (CYTK) | 0.6 | $5.9M | 200k | 29.46 |
|
|
Biontech Se Sponsored Ads (BNTX) | 0.6 | $5.8M | -24% | 53k | 108.64 |
|
Glaukos (GKOS) | 0.6 | $5.5M | -23% | 73k | 75.25 |
|
Intra Cellular Therapies (ITCI) | 0.5 | $4.9M | 95k | 52.09 |
|
|
Veeva Sys Cl A Com (VEEV) | 0.5 | $4.7M | -34% | 23k | 203.45 |
|
Immunocore Hldgs Ads (IMCR) | 0.5 | $4.6M | 89k | 51.90 |
|
|
Xencor (XNCR) | 0.5 | $4.5M | 225k | 20.15 |
|
|
R1 RCM (RCM) | 0.5 | $4.5M | 300k | 15.07 |
|
|
Iovance Biotherapeutics (IOVA) | 0.5 | $4.3M | +11% | 950k | 4.55 |
|
Oscar Health Cl A (OSCR) | 0.5 | $4.3M | NEW | 770k | 5.57 |
|
Dex (DXCM) | 0.5 | $4.2M | NEW | 45k | 93.30 |
|
Revance Therapeutics (RVNC) | 0.4 | $4.1M | +194% | 362k | 11.47 |
|
Royalty Pharma Shs Class A (RPRX) | 0.4 | $4.1M | 150k | 27.14 |
|
|
Nuvalent Inc-a (NUVL) | 0.4 | $4.0M | 86k | 45.97 |
|
|
Evolent Health Cl A (EVH) | 0.4 | $3.9M | 145k | 27.23 |
|
|
Bridgebio Pharma (BBIO) | 0.4 | $3.6M | 135k | 26.37 |
|
|
West Pharmaceutical Services (WST) | 0.4 | $3.4M | 9.0k | 375.21 |
|
|
Health Catalyst (HCAT) | 0.3 | $3.2M | 320k | 10.12 |
|
|
Moderna (MRNA) | 0.3 | $3.1M | -33% | 30k | 103.29 |
|
Bio-techne Corporation (TECH) | 0.3 | $2.9M | -10% | 43k | 68.07 |
|
10x Genomics Cl A Com (TXG) | 0.3 | $2.8M | -50% | 68k | 41.25 |
|
Axsome Therapeutics (AXSM) | 0.3 | $2.8M | 40k | 69.89 |
|
|
Harmony Biosciences Hldgs In (HRMY) | 0.3 | $2.7M | -61% | 82k | 32.77 |
|
Meiragtx Holdings (MGTX) | 0.3 | $2.6M | 539k | 4.91 |
|
|
Olink Hldg Ab Sponsored Ads (OLK) | 0.3 | $2.4M | 166k | 14.75 |
|
|
Centene Corporation (CNC) | 0.2 | $2.1M | NEW | 30k | 68.88 |
|
Edwards Lifesciences (EW) | 0.2 | $2.0M | 29k | 69.28 |
|
|
Viking Therapeutics (VKTX) | 0.2 | $2.0M | 180k | 11.07 |
|
|
Igm Biosciences (IGMS) | 0.2 | $1.7M | 200k | 8.35 |
|
|
Arvinas Ord (ARVN) | 0.2 | $1.7M | 85k | 19.64 |
|
|
Relay Therapeutics (RLAY) | 0.2 | $1.6M | 190k | 8.41 |
|
|
Intellia Therapeutics (NTLA) | 0.2 | $1.6M | 50k | 31.62 |
|
|
Inspire Med Sys (INSP) | 0.1 | $1.4M | -54% | 7.0k | 198.44 |
|
Tg Therapeutics (TGTX) | 0.1 | $1.3M | +190% | 160k | 8.36 |
|
Inmune Bio Ord (INMB) | 0.1 | $1.2M | 178k | 6.84 |
|
|
Essa Pharma Com New (EPIX) | 0.1 | $1.1M | 357k | 3.09 |
|
|
Allogene Therapeutics (ALLO) | 0.1 | $951k | 300k | 3.17 |
|
|
Outset Med (OM) | 0.1 | $544k | -84% | 50k | 10.88 |
|
Mersana Therapeutics (MRSN) | 0.1 | $508k | 400k | 1.27 |
|
|
Thermo Fisher Scientific (TMO) | 0.0 | $253k | 500.00 | 506.17 |
|
Past Filings by Rhenman & Partners Asset Management AB
SEC 13F filings are viewable for Rhenman & Partners Asset Management AB going back to 2013
- Rhenman & Partners Asset Management AB 2023 Q3 restated filed Nov. 13, 2023
- Rhenman & Partners Asset Management AB 2023 Q3 filed Nov. 9, 2023
- Rhenman & Partners Asset Management AB 2023 Q2 filed Aug. 11, 2023
- Rhenman & Partners Asset Management AB 2023 Q1 filed May 12, 2023
- Rhenman & Partners Asset Management AB 2022 Q4 filed Feb. 13, 2023
- Rhenman & Partners Asset Management AB 2022 Q3 filed Nov. 14, 2022
- Rhenman & Partners Asset Management AB 2022 Q2 filed Aug. 12, 2022
- Rhenman & Partners Asset Management AB 2022 Q1 filed May 13, 2022
- Rhenman & Partners Asset Management AB 2021 Q4 filed Feb. 11, 2022
- Rhenman & Partners Asset Management AB 2021 Q3 filed Nov. 12, 2021
- Rhenman & Partners Asset Management AB 2021 Q2 filed Aug. 13, 2021
- Rhenman & Partners Asset Management AB 2021 Q1 filed May 14, 2021
- Rhenman & Partners Asset Management AB 2020 Q4 filed Jan. 19, 2021
- Rhenman & Partners Asset Management AB 2020 Q3 filed Oct. 13, 2020
- Rhenman & Partners Asset Management AB 2020 Q2 filed July 16, 2020
- Rhenman & Partners Asset Management AB 2020 Q1 filed April 16, 2020